Delcath Systems, Inc. ( (DCTH) ) has released its Q3 earnings. Here is a breakdown of the information Delcath Systems, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Delcath Systems, Inc. is an interventional oncology company specializing in the treatment of primary and metastatic liver cancers through its proprietary products, HEPZATO KIT and CHEMOSAT, which deliver high-dose chemotherapy to the liver while minimizing systemic exposure.
Delcath Systems reported a significant increase in revenue for the third quarter of 2025, reaching $20.6 million compared to $11.2 million in the same period last year. The company highlighted the progress in its clinical programs, including the initiation of a global Phase 2 trial for liver-dominant metastatic colorectal cancer and positive results from the CHOPIN trial for metastatic uveal melanoma.
Key financial metrics for the quarter included a notable rise in HEPZATO KIT revenue to $19.3 million and a gross margin of 87%. Despite a decrease in net income to $0.8 million from $1.9 million the previous year, the company achieved a positive adjusted EBITDA of $5.3 million. Delcath also reported a strong cash position with $88.9 million in cash and investments.
Strategically, Delcath continues to expand its clinical trials and commercial activities, with 25 active centers across the U.S. and ongoing trials in Europe. The company anticipates total revenue for 2025 to be between $83 and $85 million, with consistent positive cash flow and adjusted EBITDA each quarter.
Looking ahead, Delcath Systems remains optimistic about its growth prospects, driven by the clinical validation of its products and ongoing expansion efforts. The company aims to deliver long-term value to both patients and shareholders through its innovative oncology treatments.